Five Companies Transforming the Future of Breast Cancer Care

五家转变乳腺癌治疗未来的公司

2020-02-27 01:40:25 CISION

本文共2761个字,阅读需7分钟

When caught early enough, the five-year survival rates are 99%, says the American Cancer Society. However, early detection is essential, which is why experts strongly advised screening. After all, "Where the breast cancer is located, where it has spread to, how big it is—all that plays a role in different treatment options for patients," says Dr. Keith Wells, a medical oncologist at Willamette Valley Cancer Institute, as quoted by KVAL13. To assist patients, companies are racing to produce cost-effective screening methods that offer greater accuracy, speed, and comfort than traditional methods. As you might expect, the market for breast imaging with existing methods has been big.  In fact, according to Meticulous Research, the global breast imaging market will be worth up to $5.13 billion, growing at a CAGR of 8.2% over the next four years. Some of the top companies leading the fight for better cancer detection include Izotropic Corporation , Hologic Inc. , Stryker Corporation , NeGenomics Inc. , and Clovis Oncology Inc. . Izotropic Corporation (CSE: IZO)(OTCPK: IZOZF) BREAKING NEWS: Izotropic Corporation has extended the terms of its exclusive global License Agreement with The Regents of the University of California. The amendments under the revised exclusive global License Agreement relate to the formal Commercialization Plan of breast CT technology developed at UC Davis Medical Center in Sacramento, CA. Due to unforeseen delays with patent prosecutions and completing important patent applications and filings, there was mutual desire by the parties to negotiate an extension.  The Company now has until January 2027 to execute on the terms agreed to under the Commercialization Plan and expects to meet the terms of the Commercialization Plan under the Licensing Agreement well before this date. In consideration of this extension, a nominal payment of $20,000 per annum will be made until commercialization terms are completed. Extending the commercialization terms and timeline is a material development for the Company and we wish to acknowledge the support and cooperation provided by the Regents of the University of California and UC Davis.   Other related developments from around the markets include: Hologic Inc. (NASDAQ: HOLX) announced today that the Company will present at these upcoming investor conferences: Cowen and Company's 40th Annual Healthcare Conference in Boston, MA on Tuesday, March 3 at 8 am ET; The Barclays Global Healthcare Conference in Miami, FL on Tuesday, March 10 at 2:35 pm ET. Stryker Corporation (NYSE: SYK) will participate in the Cowen 40th Annual Health Care Conference on Tuesday, March 3, 2020 at the Boston Marriott Copley Place in Boston, Massachusetts. Katherine Owen, Vice President, Strategy & Investor Relations, will represent the Company in a presentation scheduled for 10:40 a.m. Eastern Time. NeGenomics Inc. (NASDAQ: NEO) announced that it plans to release its fourth quarter and fiscal year 2019 financial results on Thursday, February 27, 2020. The Company has scheduled a web-cast and conference call to discuss their fourth quarter results on Thursday, February 27, 2020 at 8:30 AM EDT. Interested investors should dial (844) 602-0380 (domestic) and (862) 298-0970 (international) at least five minutes prior to the call. A replay of the conference call will be available until 8:30 AM EDT on March 5, 2020, and can be accessed by dialing (877) 481-4010 (domestic) and (919) 882-2331 (international). Clovis Oncology Inc. (NASDAQ: CLVS) reported financial results for the quarter and year ended December 31, 2019, and provided an update on Clovis' clinical development programs and regulatory and commercial outlook for 2020. "This is an encouraging time for Clovis, as we launch Rubraca in multiple European countries in the recurrent ovarian cancer maintenance indication and prepare for a potential U.S. approval and launch of Rubraca in patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer," said Patrick J. Mahaffy, CEO and President of Clovis Oncology. "We also look forward to initial clinical data from lucitanib combination studies later this year, and initiating clinical development with FAP-2286, our peptide-targeted radiopharmaceutical therapy product candidate. This program, as well as our ongoing discovery collaboration with 3B Pharmaceuticals, provides us an exciting opportunity to be a leader in an important new area of oncology drug development." DISCLAIMER:  FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated thirty five hundred dollars for news coverage of current press releases issued by Izotropic Corporation by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements. Contact Information:Media Contact email: editor@financialnewsmedia.com  +1(561)325-8757 SOURCE FinancialNewsMedia.com
美国癌症学会(American Cancer Society)( AmericanCancerSociety )说,如果及早发现,五年生存率为99%。然而,早期检测是必不可少的,这就是为什么专家强烈建议筛查。毕竟,“乳腺癌位于哪里,它已经扩散到哪里,它有多大——所有这些都在不同的治疗选择中发挥作用的患者,” Keith Wells 博士说,他是威拉米特谷癌症研究所的一名医学肿瘤学家,引用 KVAL13的话。为了帮助患者,公司正竞相生产成本效益高的筛查方法,比传统方法提供更高的准确性、速度和舒适性。正如您所期望的,现有方法的乳房成像市场很大。事实上,根据 MetricousResearch 的数据,全球乳房成像市场的价值将高达51.3亿美元,未来四年的复合年增长率为8.2%。一些领先于更好的癌症检测的公司包括 Izotropic 公司、 Hologic 公司、史赛克(Stryker)公司、 NeGenomics 公司和 Clovis 肿瘤公司。 Izotropic Corporation ( CSE : IZO )( OTCPK : IZOZF ) BREAKING NEWS : Izotropic Corporation 已延长其与加州大学 Regents 签订的全球独家许可协议的条款。修订后的全球独家许可协议下的修订涉及在加州萨克拉门托的加州大学戴维斯医学中心开发的乳腺 CT 技术的正式商业化计划。由于专利起诉和完成重要专利申请和备案工作出现不可预见的拖延,双方都希望谈判延长专利期限。公司现在必须在2027年1月之前按照《商业化计划》中约定的条款执行,并期望在此日期之前很早满足《许可协议》下的商业化计划条款。考虑到这一延期,在商业化条件完成之前,每年将支付20000美元的名义付款。延长商业化条款和时间表是公司的重大发展,我们希望感谢加州大学和加州大学戴维斯分校的董事们提供的支持和合作。 来自市场的其他相关发展包括: Hologic Inc .( NASDAQ : HOLX )今日宣布,公司将于3月3日(星期二)上午8点在美国东部时间波士顿举行的投资者会议: Cowen 和公司第40届年度保健会议;3月10日(星期二)下午2:35在佛罗里达州迈阿密举行的巴克莱全球保健会议。 史赛克(Stryker)公司( NYSE : SYK )将于2020年3月3日(星期二)在马萨诸塞州波士顿的波士顿万豪 Copley 广场参加考文第40届年度保健大会。战略与投资者关系副总裁 Katherine Owen 将代表公司参加定于东部时间(Eastern Time)上午10:40举行的演示活动。 NeGenomics Inc .( NASDAQ : NEO )宣布,计划于2020年2月27日(星期四)发布第四季度和2019财年的财务业绩。本公司已安排于二零二零年二月二十七日(星期四)上午八时三十分举行网络直播及电话会议,讨论第四季业绩。有兴趣的投资者应在来电前至少五分钟致电(844)602-0380(国内)及(862)298-0970(国际)。该电话会议的重播将于2020年3月5日上午8时30分之前提供,可通过拨打(877)481-4010(国内)和(919)882-2331(国际)进行访问。 Clovis Oncology Inc .( NASDAQ : CLVS )报告了截至2019年12月31日的季度和年度财务业绩,并提供了 Clovis 2020年临床开发计划和监管及商业前景的最新信息。“这是一个令人鼓舞的时刻,克洛维斯,因为我们推出 Rubraca 在多个欧洲国家的复发性卵巢癌维持适应症,并准备一个潜在的美国批准和推出 Rubraca 的患者 BRCA1/2突变复发,转移性蓖麻痹性前列腺癌,”帕特里克 J.Mahafy 说,克洛维斯肿瘤学首席执行官兼总裁.“我们还期待着今年晚些时候 Lucitanib 联合研究的初步临床数据,并与 FAP-2286(我们的多肽靶向放射药物治疗产品候选者)启动临床开发。这个项目,以及我们与3B 制药公司正在进行的发现合作,为我们提供了一个令人兴奋的机会,成为一个重要的肿瘤药物开发新领域的领导者。 Disclaimer : FN Media Group LLC ( FNM ),拥有并经营金融媒体。com 和 MarketNewsUpdates 。是第三方出版商和新闻传播服务提供商,通过多个在线媒体渠道传播电子信息。FNM 不以任何方式与本文提及的任何公司有关联。FNM 及其附属公司是新闻传播解决方案提供商,不是注册经纪人/交易商/分析师/顾问,不持有投资许可证,不得出售、要约出售或要约购买任何证券。FNM 的市场更新、新闻提醒和公司简介不是购买、出售或持有证券的邀请或建议。本新闻稿中的材料是严格的信息,是绝不能解释或解释为研究材料。强烈敦促所有读者自行进行研究和尽职调查,并在考虑任何级别的股票投资之前咨询持牌金融专业人士。本文所包含的所有材料都是重新发布的内容和细节,这些内容和细节以前是由本新闻稿中提到的公司传播的。FNM 对其读者或订户的任何投资决定概不负责。投资者在投资股票时可能会损失全部或部分投资。就目前所提供的服务而言, FNM 预计将获得非附属第三方对 Izotropic Corporation 发布的当前新闻稿的新闻报道赔偿3500美元。FNM 不持有任何在此项退租中命名的公司的股份。 本新闻稿包含经修订的1933年证券法第27A 条含义内的“前瞻性陈述”,以及经修订的1934年证券交易法第21E 条含义内的“前瞻性陈述”,且该等前瞻性陈述是根据1995年《私人证券诉讼改革法案》的安全港条款作出的。“前瞻性陈述”描述未来的期望、计划、结果或策略,通常在前面加上“可能”、“未来”、“计划”或“计划”、“将”或“应该”、“预期”、“预期”、“草案”、“最终”或“预计”等词。请注意,此类声明可能会受到多种风险和不确定性的影响,这些风险和不确定性可能导致未来的情况、事件或结果与前瞻性声明中预测的情况、事件或结果存在重大差异。包括因各种因素导致的实际结果可能与前瞻性陈述中预测的结果存在重大差异的风险,以及公司在10-K 或10-KSB 表格上的年度报告以及该公司向证券交易委员会提交的其他文件中识别的其他风险。在评估包含在此的前瞻性陈述时,您应考虑这些因素,而不应过分依赖此类陈述。本新闻稿中的前瞻性陈述自本公告发布之日起作出, FNM 不承担更新此类声明的义务。 联系人信息:媒体联系人电子邮件:编辑器@ financialstomedia.com +1(561)325-8757 财经新闻媒体.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文